# Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

> **NCT05533632** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 104 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT05533632
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-25
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-01-18
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05533632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05533632, "Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05533632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*